A pioneering clinical trial led by the Vall d’Hebron University Hospital in Barcelona demonstrates that a new neuroblastoma combination therapy significantly improves outcomes for children with aggressive forms of the disease. This study, conducted in collaboration with the University of Birmingham, reveals that blending chemotherapy with immunotherapy offers tangible benefits for patients with relapsed or treatment-resistant neuroblastoma.
Neuroblastoma is a rare and often aggressive paediatric cancer accounting for approximately 10% of all childhood cancer cases. The findings, published in the Journal of Clinical Oncology, suggest a potential shift in how clinicians approach cases where standard treatments have failed.
Your browser does not support the video tag.Home » Neuroblastoma Combination Therapy: New Trial Shows Significant Survival Benefits
The BEACON Initiative and Neuroblastoma Combination Therapy
The research was carried out as part of the BEACON initiative, a European effort designed to identify more effective treatments for relapsed neuroblastoma. The trial involved 65 children and adolescents aged between one and eighteen, recruited from 29 medical centres across seven European countries.
Participants were divided into two cohorts to evaluate the efficacy of the new approach:
- Standard Group: 22 patients received chemotherapy alone.
- Combination Group: 43 patients received chemotherapy combined with dinutuximab beta, an antibody designed to target and eliminate tumour cells.
The protocol required patients to undergo six cycles of treatment. Notably, 13 children initially assigned to the chemotherapy-only group were later switched to the combination therapy when it became evident that the standard treatment was not yielding sufficient results.
Significant Survival Improvements with Neuroblastoma Combination Therapy
The trial results highlight a marked improvement in patient outcomes when immunotherapy is introduced. Researchers measured success primarily through tumour volume reduction and progression-free survival—the length of time a patient lives with the disease without it worsening.
The data showed that the neuroblastoma combination therapy achieved a tumour reduction in 30.2% of cases, compared to just 18.2% in the group receiving only chemotherapy.
Even more significant were the figures regarding progression-free survival:
- Patients on the dual therapy survived without tumour progression for an average of 11.1 months.
- Patients on chemotherapy alone averaged just 3.8 months.
One year after joining the study, 44% of the children receiving the combination treatment were alive with stable disease, compared to 27% of those treated solely with chemotherapy.
Targeting Paediatric Cancer with Neuroblastoma Combination Therapy
The drug at the centre of this trial, dinutuximab beta, is one of the few pharmaceutical agents developed specifically for paediatric cancer. By combining this targeted immunotherapy with traditional chemotherapy, the BEACON trial provides strong evidence for a new therapeutic strategy.
These findings offer renewed hope for families facing relapsed neuroblastoma. Therefore, this neuroblastoma combination therapy provides a scientifically backed option that significantly extends the period of disease stability compared to conventional methods.
Apply to join our community of Entrepreneurs, Senior Executives and Founders at Bizcelona .
